Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell

MT Newswires Live

Feb 26, 2025

Ardelyx (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperphosphatemia has received approval from China's Center for Drug Evaluation of the National Medical Products Administration.

Tenapanor received approval to control serum phosphorus levels in dialysis patients with chronic kidney disease with an inadequate response or who are intolerant to phosphorus binders, Ardelyx said.

The company said that following the approval, it will receive a $5 million milestone payment from its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development. Ardelyx said that under the terms of their license agreement, it is eligible to receive up to $100 million in additional developmental and commercialization milestones and tiered royalty payments on net sales of mid-teens to 20%.

The company said Shanghai Fosun Pharmaceutical has the exclusive rights to market and sell tenapanor in China, Hong Kong and Macau, with tenapanor to be marketed with the Chinese trade name Wan Ti Le.

Shares were 1.4% higher ahead of Wednesday's opening bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514555058"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514555058\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514555058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514555058","market":"sg","top_or_hot":-1,"title":"Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperphosphatemia has received approval from China's Center for Drug Evaluation of the National Medical Products Administration.</p><p>Tenapanor received approval to control serum phosphorus levels in dialysis patients with chronic kidney disease with an inadequate response or who are intolerant to phosphorus binders, Ardelyx said.</p><p>The company said that following the approval, it will receive a $5 million milestone payment from its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development. Ardelyx said that under the terms of their license agreement, it is eligible to receive up to $100 million in additional developmental and commercialization milestones and tiered royalty payments on net sales of mid-teens to 20%.</p><p>The company said Shanghai Fosun Pharmaceutical has the exclusive rights to market and sell tenapanor in China, Hong Kong and Macau, with tenapanor to be marketed with the Chinese trade name Wan Ti Le.</p><p>Shares were 1.4% higher ahead of Wednesday's opening bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-26 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperphosphatemia has received approval from China's Center for Drug Evaluation of the National Medical Products Administration.</p><p>Tenapanor received approval to control serum phosphorus levels in dialysis patients with chronic kidney disease with an inadequate response or who are intolerant to phosphorus binders, Ardelyx said.</p><p>The company said that following the approval, it will receive a $5 million milestone payment from its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development. Ardelyx said that under the terms of their license agreement, it is eligible to receive up to $100 million in additional developmental and commercialization milestones and tiered royalty payments on net sales of mid-teens to 20%.</p><p>The company said Shanghai Fosun Pharmaceutical has the exclusive rights to market and sell tenapanor in China, Hong Kong and Macau, with tenapanor to be marketed with the Chinese trade name Wan Ti Le.</p><p>Shares were 1.4% higher ahead of Wednesday's opening bell.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514555058","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514555058","pubTimestamp":1740579982,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ardelyx (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperphosphatemia has received approval from China's Center for Drug Evaluation of the National Medical Pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARDX":"Ardelyx"},"translate_title":"Ardelyx称中国批准治疗高磷血症的新药申请Tenapanor；分享盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Ardelyx (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperphosphatemia has received approval from China's Center for Drug Evaluation of the National Medical Products Administration.Tenapanor received approval to control serum phosphorus levels in dialysis patients with chronic kidney disease with an inadequate response or who are intolerant to phosphorus binders, Ardelyx said.The company said that following the approval, it will receive a $5 million milestone payment from its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development. Ardelyx said that under the terms of their license agreement, it is eligible to receive up to $100 million in additional developmental and commercialization milestones and tiered royalty payments on net sales of mid-teens to 20%.The company said Shanghai Fosun Pharmaceutical has the exclusive rights to market and sell tenapanor in China, Hong Kong and Macau, with tenapanor to be marketed with the Chinese trade name Wan Ti Le.Shares were 1.4% higher ahead of Wednesday's opening bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}